MedPath

Music Therapy Songwriting and Mental Health in Neonatel Intensive Care Unit (NICU) Parents

Not Applicable
Not yet recruiting
Conditions
Mental Health Impairment
Registration Number
NCT06423092
Lead Sponsor
Claudia Aristizábal
Brief Summary

The mental health of parents of preterm newborns (PTNB) is negatively affected by prolonged hospitalization of the PTNB in the intensive care unit. This produces changes in the role of the parents and the bond with the newborn, leading to states of depression, anxiety, and stress. Several strategies, including music therapy, have been implemented to mitigate the negative impact on the parents' mental health.

The main objectives of the proposed trial are to determine whether Music Therapy (MT) songwriting combined with standard care (SC) during NICU stay is superior to SC alone in reducing the risk of postpartum depression in at-risk parents of preterm children at the end of treatment, and understand the lived experiences of participating parents who received music therapy for their mental health.

Detailed Description

This study employs a multicenter, mixed-method approach, with a quantitative component that will be a pragmatic parallel controlled randomized clinical trial (RCT) and a qualitative component that will include phenomenological study. The quantitative component will assess depression and anxiety, which will be evaluated with the Edinburgh Postnatal Depression Scale (EPDS) and the Generalized Anxiety Disorder Scale (GAD-7), respectively. Secondary outcomes will be resilience, coping, stress, and mental well-being. These outcomes will be measured in the first week of hospitalization (baseline measure) and then in weeks 1, 2, and 3 of the intervention. Changes in scores will be assessed to identify the effect, and mediating variables will be determined by multivariate analysis. Semi-structured interviews will be conducted on the parents' experience of music therapy songwriting for the baby.

The study will provide data on the effect of music therapy songwriting on the mental health of parents of neonates with brain injuries (PTNB) versus standard care and will document the lived experience of music therapy songs. The results may inform the standardization of this strategy in neonatal intensive care units (NICUs) to support and accompany parents and decrease the impact on their mental health.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
102
Inclusion Criteria
  • The study population consisted of parents/caregivers of newborns hospitalized in neonatal intensive care units (NICUs) with gestational ages of ≤32 weeks and expected hospitalizations of at least three weeks. In the case of a twin pregnancy, the firstborn infant was randomly assigned to one of the intervention groups, while both infants received the same treatment according to the outcome of randomization.
  • Mother a total score of ≥10 and/or father a total score of ≥7 on the EPDS (Edinburgh Postnatal Depression Scale)
  • Mother and/or father a total score of ≥8 on the GAD-7 (Generalized Anxiety Disorder Scale)
Exclusion Criteria
  • Parents/caregivers with known auditory problems that prevent participation in MT.

Moreover parents/caregivers with a documented mental illness or cognitive impairment that prevents them from being able to complete the study intervention or outcome assessments.

  • Parents/caregivers of premature infants in palliative or end-of-life care, infants with known hearing impairment, or infants in the custody of social services.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Postpartum depressionIt will be measured during the first week of hospitalization (baseline measurement) and at weeks 1, 2, and 3 of the intervention.

Postpartum depression will be assessed with the Edinburgh Postnatal Depression Scale (EPDS). This scale has values between 0 to 30 points. Higher scores mean a worse outcome.

Secondary Outcome Measures
NameTimeMethod
AnxietyIt will be measured during the first week of hospitalization (baseline measurement) and at weeks 2 and 3 of the intervention.

Anxiety will be assessed with the Generalized Anxiety Disorder Scale (GAD-7). Minimum and maximum possible scores of 0 and 21 respectively. Higher scores mean a worse outcome.

Well-beingIt will be measured during the first week of hospitalization (baseline measurement) and at weeks 2 and 3 of the intervention.

The Warwick Edinburgh Mental Well-Being Scale (WEMWBS) will be employed to assess well-being. Minimum and maximum possible scores of 14 and 70 respectively. Higher scores mean a better wellbeing.

ResilienceIt will be measured during the first week of hospitalization (baseline measurement) and at week 3 of the intervention.

Resilience will be assessed with the Brief Resilience Scale (BRS). Participants respond on a 5-point Likert scale, ranging from 1 (Strongly Disagree) to 5 (Strongly Agree) and giving a range from 6-30. Higher scores mean a better resilience.

StressIt will be measured during the first week of hospitalization (baseline measurement) and at week 3 of the intervention.

Stress will be assessed with the 10-item Perceived Stress Scale (PSS-10). Answers are then scored on Likert scale from 0 "Never" to 4 "Very often". Higher scores indicate higher levels of perceived stress.

CopingIt will be measured during the first week of hospitalization (baseline measurement) and at week 3 of the intervention.

Stress response will be assessed with the Brief COPE Inventory (Brief-COPE). Scores are presented on Likert scale from 1 " I haven't been doing this at all" to 4 "I've been doing this a lot".

Trial Locations

Locations (5)

Clínica Iberoamérica en Colombia

🇨🇴

Barranquilla, Atlántico, Colombia

Clinica Pediátrica

🇨🇴

Bogotá, Cundinamarca, Colombia

Clínica Universitaria Colombia

🇨🇴

Bogotá, Cundinamarca, Colombia

Clínica Keralty Ibagué

🇨🇴

Ibagué, Tolima, Colombia

University of Gdańsk

🇵🇱

Gdańsk, Poland

Clínica Iberoamérica en Colombia
🇨🇴Barranquilla, Atlántico, Colombia
Mark Ettenberger, PhD
Contact
+57 605 3319424
mark.ettenberger@gmx.at

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.